Amylgen is a french CRO proposing to test your products for their neuroprotective properties in rodent models, helping drug discovery or brain health claims
@Amylgen and @Imactiv3D propose novel 3D imaging of brains from preclinical models of neurodegenerative diseases or of aging in rodents. You are invited to the presentation of this synergy https://t.co/RMzzxk6pxt
J-1 avant le #Webinaire en direct "Les membres AFSSI ont la parole" où sera mis à l'honneur @Amylgen 🗓️ Demain, 10h 🗓️
Pour ne rien manquer, inscrivez-vous gratuitement ici 👉 : https://t.co/WTToG6Sma6
@Amylgen is proud to contribute to the study published with DuPont Nutrition: Collaborative research study shows certain bacteria such as Lactobacillus paracasei Lpc-37® can alleviate adverse effects of stress in rodents. Read full press release here https://t.co/pRi8onbRJb
The FBB is #mediapartner for the @marketsmarkets Gen-Next Probiotics and Microbiome #congress. This 1st day was also a great opportunity to attend the talk of our member at @Amylgen. Bonus picture: view on our San Diego downtown and the Coronado bridge from the conference place!
[ALZHEIMER] 64 volontaires participent à un essai clinique au @CHU_Montpellier avec un casque de neurostimulation.
@DrAudreyGabelle@gblvt
https://t.co/I7G32vkwml
#Amylgen and Neuron-Experts Announce Exclusive, Strategic Partnership providing a new combined in-vitro & in-vivo preclinical offer for a rapid efficacy assessment of your products in neurodegenerative diseases https://t.co/Powt0fEJwS
If you’re attending #dgnkongress this week, don’t miss the chance to connect with @Pharnext’s team at booth C32 to learn about #PLEOTHERAPY and our results on #CMT https://t.co/KbdWMhUkWT…
#Amylgen has organized a Focus day with #Lallemand and ten North American Scientists at the #Dinisi Hotel (Castries). A very productive day. Thanks to all for your participation.
#Amylgen will be attending Pharmabiotics 2019 13-14 March 2019. Amylgen is involved in various studies exploring gut-brain axis and the effect of gut microbiota on brain function.
"The neuroprotective effect of a new photobiomodulation technique on Abeta25-35 induced toxicity dramatically impacts the gut microbiota dysbiosis" by Laura Auboyer, PhD @Amylgen@Vaiomer#CTAD2018
@Amylgen will be presenting a poster at the Gut-Brain Axis conference in Paris on September 6th and 7th. Our services allow you to demonstrate how gut microbiota modification may impact on brain function (memory, anxiety, depression, neuroprotection...)
@Amylgen and @cilcare partner to propose new models for testing substances aimed to improve cognition and hearing during ageing process. Happy to introduce you our old friend SAM. https://t.co/QHjcBT4vxd
@Amylgen will be participating to Neuro 4D Conference Advances in Drug Discovery for Proteopathic neurodegenerative diseases meeting in Mainz 4 - 5th June 2018. Its preclinical models will be presented. https://t.co/LI2fKzp10Q
@Amylgenwilll be present at the AAT-AD/PD™ meeting in Torino 15-18 March.
A poster will be presented during the session A2.g on 17 March entitled :
"Abeta 25-35 peptide-induced toxicity in mice is relieved by application of a photobiomodulation technique